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Introduction
 The mechanisms of progressive glomerulonephritis remain 
mostly unknown. Many studies have found renal activation 
of the renin-angiotensin system (RAS) and increased local 
angiotensin II (Ang II) production in human and experi-
mental kidney diseases.1,2 Blockade of Ang II by using 
angiotensin-converting enzyme (ACE) inhibitors or Ang 
receptor type 1 (AT1) antagonists, are one of the best options 
to treat human kidney diseases.1 Ang II blockers reduce 
proteinuria, delay renal fibrosis and preserve kidney func-
tion. However, use of Ang II blockers does not prevent dis-
ease progression and therefore it is necessary to investigate 
further the mechanisms of Ang II renal damage.
Experimental studies have shown that Ang II actively 
participates in the regulation of the inflammatory response 
in the kidney, being the activation of the nuclear factor-κB 
(NF-κB) pathway an important mechanism of Ang II–
induced inflammatory process.2,3 Ang II binds to specific 
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Abstract
Introduction: The nuclear factor-κB (NF-κB) is an important regulator of the inflammatory response. Angiotensin II 
(Ang II) activates the NF-κB pathway linked to renal inflammation. Although both AT1 and AT2 receptors are involved 
in Ang II-mediated NF-κB activation, the biological processes mediated by each receptor are not fully characterized. 
Interleukin-1β (IL-1β) is an important macrophage-derived cytokine that regulates immune and inflammatory processes, 
activating intracellular pathways shared with Ang II, including the NF-κB.
Materials and methods: In vitro studies were done in primary cultured rat mesangial cells. NF-κB pathway was 
evaluated by phosphorylated levels of p65/IκB and DNA binding activity. The Ang II receptor subtype was determined 
by pretreatment with AT1 and AT2 antagonists.
Results: In mesangial cells the simultaneous presence of Ang II and IL-1β caused a synergistic activation of the NF-κB 
pathway and a marked upregulation of proinflammatory factors under NF-κB control, including monocyte chemoattractant 
protein-1. The AT1, but not AT2, antagonist abolished the synergistic effect on NF-κB activation and proinflammatory 
genes caused by coincubation of Ang II and IL-1β.
Conclusions: These data indicates that Ang II, via AT1/NF-κB pathway activation, cooperates with IL-β to increase the 
inflammatory response in mesangial cells.
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receptors, AT1 and AT2, to activate cellular responses.3,4 The 
AT1 receptor mediates vasoconstriction, upregulation of 
growth factors and fibrosis.3,4 In several cell types, Ang II 
activates NF-κB via AT2 receptors.5 Interestingly, both AT1 
and AT2 receptors are involved in Ang II-mediated NF-κB 
activation in the kidney.6 However, the biological processes 
mediated by each receptor are not fully characterised.
During renal injury, many growth factors and cytokines 
are upregulated, and it is possible that those factors may 
influence the response of renal cells to Ang II.2 The mac-
rophage derived cytokine interleukin-1β (IL-1β) exerts a 
broad range of biological activities.7 IL-1β is a proinflam-
matory cytokine that participates in human and experi-
mental renal diseases.8–11 Initial studies in the model of 
anti-Thy-1 nephritis demonstrated that IL-1β receptor 
blockade reduced glomerular macrophage accumulation.8 
More recently in an experimental model of type II diabetes 
the IL-1β receptor antagonist, anakinra, presented protec-
tive effects,12 showing the involvement of this cytokine in 
renal inflammation. IL-1β activates several intracellular 
pathways shared with Ang II, including the NF-κB path-
way.2,7,13–15 We describe here how the simultaneous pres-
ence of Ang II and the proinflammatory cytokine IL-1β in 
rat mesangial cells amplified the inflammatory response, 
characterised by a synergism of NF-κB activation and 
upregulation of proinflammatory mediators, including 
monocyte chemoattractant protein-1 (MCP-1) and inter-
leukin-6 (IL-6), by a process mediated by AT1. These data 
indicate that in inflammatory conditions, the AT1 blockade 
could exert additional anti-inflammatory properties by 
modulating cytokine-induced NF-κB activation.
Materials and methods
Reagents
Recombinant human IL-1β was obtained from Peprotech. 
Ang II was obtained from Tocris. NF-κB consensus oligo-
nucleotide was from Promega Corp. The AT1 and AT2 
receptor antagonist used were Valsartan (Novartis) and 
PD123319 (Sigma). The inhibitors used were from: 
BAY11-7082 and Parthenolide (NF-κB inhibitors) from 
Calbiochem. Cells were preincubated with all inhibitors 
for one hour before adding the stimulus. None of the inhib-
itors were toxic at the doses used. Culture reagents were 
purchased from Gibco BRL.
Cell culture studies
Rat mesangial cells (MCs) were cultured from isolated glo-
meruli by several sieving techniques and differential cen-
trifugations.16,17 Glomerular mesangial cells were 
characterised by phase contrast microscopy, presenting 
positive staining for desmin and vimentin, and negative 
staining for keratin and factor VIII antigen, that exclude epi-
thelial and endothelial contamination, respectively. Cells 
were grown in Roswell Park Memorial Institute (RPMI) 
1640 medium, supplemented with 100 U/ml penicillin, 100 
μg/ml streptomycin, and 2 mM glutamine in the presence of 
20% heat-inactivated foetal bovine serum (FBS) and cul-
tured at 37ºC in 5% CO2 atmosphere. At confluence cells 
were made quiescent for 48 h in RPMI with 0.5% FBS 
medium then different studies were performed. The experi-
ments were done with cultured MCs with 0 or 1 passage.
Gene studies
RNA was isolated by Tripure (Roche, Barcelona, Spain). 
cDNA was synthesised using High Capacity cDNA Archive 
Kit (Applied Biosystems, Foster City, California, USA) using 
2 μg of total RNA primed with ramdon hexamer primers fol-
lowing the manufacturer’s instructions. Real-time polymer-
ase chain reaction (PCR) reactions were performed on ABI 
Prism 7500 sequence detection PCR system (Applied 
Biosystems) according to manufacturer’s protocol. Assay IDs 
used were: IL-6, Rn00561420_m1; MCP-1, Rn00580555_
m1; Vascular Cell Adhesion Molecule 1 (VCAM-1), 
Rn00563627_m1; IL-1β, Rn00580432_m1. Data were nor-
malised with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and 18S ribosomal RNA expression (assay IDs: 
Rn99999916_s1 and Hs99999901_m1 respectively). The 
mRNA copy numbers were calculated for each sample by the 
instrument software using Ct value (‘arithmetic fit point anal-
ysis for the lightcycler’). Results were expressed in copy 
numbers, calculated relative to unstimulated cells, after nor-
malisation against GAPDH and 18S.
Protein studies
Cells were homogenised in lysis buffer (170 mM Tris 
HCl, 22% glycerol, 2.2% sodium dodecyl sulphate (SDS), 
0.1 mM phenylmethylsulphonyl fluoride, ortovanadate 
and protease inhibitor cocktail) and then separated by 
SDS-polyacrilamide gel electrophoresis. IκBα and 
phosphorylated-IκBα (p-IκBα) protein levels were deter-
mined in cytosolic protein extracts by Western blot analy-
sis.17 Proteins were quantified in all samples by 
bicinchoninic acid assay (BCA) method and a fixed 
amount of protein (50 μg) was loaded in each lane. The 
quality of proteins and efficacy of protein transfer was 
evaluated by Ponceau red staining. α-Tubulin or GAPDH 
were used as loading control. Antibodies employed were: 
phospho-p65 (Ser536) (#3031) from Cell Signaling, 
phospho-IκB Kinase α (IKKα) (Thr23) (sc-101706), total 
IκBα (sc-371), phospho-IκBα (Ser32) (sc-8404), total 
IκBα (sc-371), and IL1β receptor antibodies were from 
Santa Cruz Biotechnology, GAPDH (MAB374) was from 
Chemicon International, α-Tubulin (T5168) was from 
Sigma and peroxidase-conjugated secondary antibodies 
(Amersham). MCP-1 release was evaluated by enzyme-
linked immunosorbent assay (ELISA) (RayBiotech).
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Immunofluorescence
MCs were seeded in 24-well plates over crystal coverslips. 
After a 24 h serum-starvation step, cells were stimulated for 
indicated times. Then, cells were fixed in Merckofix (Merck, 
Millipore, Temecula, California, USA), treated with 0.1% 
Triton-X100, blocked with 4% BSA in PBS and incubated 
with primary antibody against p65 subunit (sc-372, Santa 
Cruz Biotechnology) overnight at 4ºC. After washing, cells 
were incubated with fluorescein isothiocyanate (FITC)-
conjugated secondary antibody (Sigma) and nuclei were 
stained with 1 μg/mL propidium iodide. The absence of pri-
mary antibody was the negative control. Samples were 
mounted in Mowiol 40-88 (Sigma) and examined by a laser 
scanning confocal microscope (Leica TSC SP5).
Electrophoretic mobility shift assay (EMSA)
Nuclear and cytosolic extracts were prepared by homogeni-
sation and centrifugation as previously described.16 NF-κB 
DNA binding activity was determined in nuclear extracts by 
binding with labelled NF-κB consensus and electrophoresis. 
The NF-κB consensus oligonucleotide (5´-AGTTGA 
GGGGACTTTCCCAGGC-3´) was 32P-end- labelled by 
incubation for 10 min at 37ºC with 10 U of T4 polynucleo-
tide kinase (Promega) in a reaction containing 10 μci of [γ-
32P]ATP, 70 mM Tris-HCl, 10 mM MgCl2, and 5 mM 
Dithiothreitol (DTT). The reaction was stopped by the addi-
tion of Ethylenediaminetetraacetic acid (EDTA) to a final 
concentration of 0.05 M. Nuclear or cellular protein (10 μg) 
was equilibrated for 10 min in a binding buffer containing 
4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 
mM NaCl, 10 mM Tris-HCl (pH 7.5), and 50 μl/ml of 
poly(dI-dC) (Pharmacia, Uppsala, Sweden). NF-κB activity 
was quantified in 10 μg of total protein of each pool, and 
experiments were done in duplicate. To assess the specificity 
of the reaction, the following controls were done: negative 
assay without cellular extracts; and competition assays with 
a 100-fold excess of unlabelled NF-κB, mutant NF-κB, an 
unspecific oligonucleotides. When competition assays were 
done, the unlabelled probe was added to this buffer 10 min 
before the addition of the labelled probe. The labelled probe 
(0.35 pmol) was added to the reaction and incubated for 20 
min at room temperature. The reaction was stopped by add-
ing gel loading buffer (250 mM Tri-HCl, 0.2% bromophenol 
blue, 0.2% xylene cyanol, and 40% glycerol), and run on a 
nondenaturing, 4% acrylamide gel at 100 V at room tem-
perature in 0.25% Tris-Borate-EDTA buffer (TBE) . The gel 
was dried and exposed to X-ray film.
Statistical analysis
The autoradiographs were scanned using the GS-800 
Calibrated Densitometer (Quantity One software from 
Bio-Rad). Results are expressed as n-fold over control as 
mean±standard error of the mean (SEM) of experiments 
made. One-way analysis of variance (ANOVA) was used 
to compare gene and/or protein expression levels between 
groups. When statistical significance was found, the 
Bonferroni post-hoc comparison test was used to identify 
differences between groups. Differences were considered 
significant at p<0.05. Statistical analyses were performed 
using the SPSS statistical software, version 16.0.
Results
The simultaneous presence of Ang II and IL-1β 
induces a synergistic effect on NF-κB pathway 
activation in cultured mesangial cells
In resting cells, NF-κB remains in the cytosol as an inactive 
complex, formed by the p50 and p65 subunits bound to the 
inhibitory subunit IκBα.18 One of the earliest events in the 
canonical NF-κB pathway is the activation of the IKK 
complex,19 followed by the phosphorylation of the compo-
nents of NF-κB complex IκBα and p65 subunit,18,20 there-
fore phosphorylation levels of these proteins were used as 
markers of NF-κB activation. In cultured rat mesangial 
cells, both Ang II and IL-1β induced the phosphorylation of 
IKKα, IκBα and p65, alone or in coincubation (Figure 1). 
The phosphorylation of the inhibitory IκBα subunit targets 
it for an ubiquitin-proteasome dependent degradation.18 
Both Ang II and IL-1β induced the diminution of cytosolic 
IκBα protein levels, indicating that this protein is degraded 
(Figure 1(c) and 1(d)). Interestingly, cells co-incubated 
with both factors, these effects were more marked, as 
clearly shown by the ratio of phosphorylated-IκBα versus 
total IκBα (Figure 1(c) and 1(d)).
NF-κB transcription factors consist of five distinct 
DNA-binding subunits, referred to as p50, p52, p65/Rel A, 
c-Rel, and Rel-B. We have analysed the NF-κB subunits in 
IL-1β and Ang II-treated cells, by a supershift assay using 
selective antibodies specifically for the NF-κB/Rel pro-
teins, showing the involvement of p65/p50 heterodimer 
(data not shown). To further demonstrate the role of p65 
NF-κB subunit in this process we have carried out confocal 
microscopy experiments. As shown in Figure 2(a), in 
unstimulated cells p65 NF-κB subunit is located in the 
cytosol, whereas after stimulation with IL-1β or Ang II p65 
is translocated into the nuclei. The coincubation of both 
cytokines caused a synergistic effect on p65 nuclear locali-
sation compared to each stimulus alone (Figure 2(a)). The 
active NF-κB complex is translocated into the nucleus 
where it binds to specific DNA sequences to regulate gene 
transcription.18 IL-1β and Ang II caused a rapid activation 
of NF-κB DNA binding activity, observed by EMSA exper-
iments after 30 min of stimulation, confirming previous 
data.16,21 When both stimuli were added together a syner-
gistic effect on NF-κB DNA binding activity was found 
(Figure 2(b) and 2(c)). These data clearly demonstrate that 
the simultaneous presence of IL-1β and Ang II induced a 
synergistic activation of NF-κB pathway in cultured MCs.
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The simultaneous presence of IL-1β and Ang 
II causes overexpression of NF-κB-related 
inflammatory genes in mesangial cells
Coincubation of IL-1β and Ang II markedly increased 
MCP-1 gene expression (Figure 3(a)), and protein release 
(Figure 3(b)). Coincubation of IL-1β and Ang II caused a 
synergistic effect on IL-6 and VCAM-1 gene expression 
(Figure 3(a)). The involvement of NF-κB in the regulation 
of these genes was evaluated by using the NF-κB inhibitor, 
BAY 11-7082. Preincubation of MCs with BAY 11-7082 
reduced proinflammatory gene overexpression observed 
by coincubation of Ang II and IL-1β (data not shown), and 
blocked MCP-1 release (Figure 3(b)).
Figure 1. Angiotensin II (Ang II) and interleukin-1β (IL-1β) coincubation increased IKKα, IκBα and p65 nuclear factor-κB (NF-κB) 
phosphorylation, and diminished total IκBα protein levels in rat mesangial cells. Cells were coincubated for increasing times with 1 ng/
ml IL-1β and 10−7 M Ang II, and total and cytosolic extracts were used. α-tubulin or GAPDH were used as loading controls. Part (a) 
shows a representative Western blot of phospho-IKKα and in (b) data corrected to GAPDH levels, as n-fold as mean±standard error 
of the mean (SEM) of four experiments. Figure (c) shows a representative Western blot of IκBα and phosphorylated-IκBα. Figure 
(d) shows the ratio of phosphorylated-IκBα versus total IκBα as mean±SEM of three experiments. Figure (e) shows a representative 
Western blot of phospho-p65 NF-κB and in (f) data corrected to GAPDH levels, as n-fold as mean±SEM of four experiments. *p<0.05 
vs control.
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AT1 receptor mediates the synergistic NF-
κB activation and proinflammatory gene 
upregulation
To evaluate the Ang II receptor subtype involved in NF-κB 
synergistic activation, cells were preincubated with the 
AT1 receptor antagonist valsartan or AT2 receptor 
antagonist PD123319. Only treatment with valsartan, but 
not PD123319, markedly diminished the synergistic p65 
translocation caused by coincubation with Ang II and 
IL-1β (Figure 4(a) and 4(b)). Finally, we evaluated the 
effect of AT1 blockade on proinflammatory gene expres-
sion. Only treatment with valsartan, but not PD123319, 
markedly diminished synergistic proinflammatory gene 
Figure 2. Synergistic activation of nuclear factor-κB (NF-κB) caused by angiotensin II (Ang II) and interleukin-1β (IL-1β) in rat 
mesangial cells. Cells were coincubated with 1 ng/ml IL-1β and 10−7 M Ang II for 30 min. The p65 NF-κB subunit was localised by 
indirect immunofluorescence. Part (a) shows a representative confocal microscopy experiment of three done with similar results. 
(b) Nuclear extracts were obtained and NF-κB activity was determined by binding assay of nuclear proteins to an oligoconsensus 
labelled with γ-32[P]. The specificity of the reaction was established using competition assays with a 100-fold excess of unlabelled 
NF-κB oligonucleotide. The position of the NF-κB complexes and free-oligonucleotide is indicated. Part (b) shows a representative 
electrophoretic mobility shift assay (EMSA) experiment and in (c) data of DNA binding activity expressed as mean±standard error of 
the mean (SEM) of four experiments. *p<0.05 vs control; #p<0.05 vs Ang II; †p<0.05 vs IL-1β.
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overexpression caused by coincubation with Ang II and 
IL-1β (Figure 4(c)). These data showed that synergistic 
effect on NF-κB pathway was mainly mediated through 
AT1 receptor.
Ang II does not regulate IL-1β or its receptor in 
mesangial cells
In cultured MCs, Ang II did not regulate IL-1β mRNA lev-
els or IL-1β receptor protein levels, at least, at the time 
points evaluated (Figure 5(a) and 5(b)).
Discussion
The major signalling pathway that controls inflammation-
associated gene expression is the NF-κB pathway. Many
in vitro studies have demonstrated that proinflammatory 
cytokines such as Ang II and IL-1β activate the canonical 
NF-κB pathway in several cell types, including renal cells 
(mesangial, endothelial and tubuloepithelial cells).2,5,16,21 
This canonical pathway is characterised by the activation of 
the IKK complex,22 leading to the phosphorylation of IκBα 
and p65, and subsequent nuclear translocation of the active 
NF-κB complex, where it acts as a transcription factor.19 In 
vivo studies have described how Ang II induced the phos-
phorylation of IKKα and IκBα, associated with NF-κB 
translocation to the nuclei and increased NF-κB activity in 
several tissues, including kidney,6,23 aorta24 and heart.25 In 
the kidney, Ang II increased p65 NF-κB phosphorylation at 
serine residue,23 a key regulatory site in the COOH-terminal 
transactivation domain.19 We have observed that in cultured 
MCs the simultaneous presence of IL-1β and Ang II caused 
a synergistic increase in the phosphorylation of IKK, IκBα 
and p65, as well as downstream effects, including p65 
nuclear localisation and increased NF-κB DNA binding 
activity. There is a plethora of κB-dependent genes, pre-
dominantly regulating inflammation and cellular growth/
survival.26 Ang II induces many proinflammatory genes via 
NF-κB, and regulates renal inflammation through this path-
way.2,16,21 We have found that coincubation of IL-1β and 
Ang II caused a marked overexpression of key NF-κB-
controlled proinflammatory mediators, such as MCP-1 and 
IL-6. Moreover, blockade of NF-κB abrogates the synergis-
tic effect of MCP-1 release caused by the coincubation of 
IL-1β and Ang II. Renal damage is associated with overex-
pression of a great variety of growth factors and cytokines, 
which influences the progression of kidney diseases. MCP-1 
is an important molecule in renal injury that contributes to 
monocyte recruitment, promoting an inflammatory environ-
ment.27 In human diabetic nephropathy activation of the 
canonical NF-κB pathway has been correlated to MCP-1 
upregulation.18 Moreover, increased urinary MCP-1 was 
associated with later stage disease of diabetic nephropathy.28 
Dysregulation of IL-6 activity or its signalling cascade has 
been implicated in the pathogenesis of a number of inflam-
matory diseases,29 including chronic kidney disease. Our 
data support the hypothesis that increased MCP-1 and IL-6 
by resident renal cell exposure to a combination of Ang II 
and IL-1β may lead to further attraction of inflammatory 
Figure 3. (a) Cotreatment with interleukin-1β (IL-1β) and 
angiotensin II (Ang II) increased proinflammatory gene expression 
in mesangial cells. Cells were treated with 1 ng/ml IL-1β and 
10−7 M Ang II for 18 h. Gene expression was evaluated by real-
time PCR. (b) Cotreatment with IL-1β and Ang II increased 
monocyte chemoattractant protein-1 (MCP-1) release by a NF-
κB mediated process. Some cells were pretreated with 10–5 M 
of BAY 11-7082, for one hour, before stimulation with 1 ng/ml 
IL-1β and 10−7 M Ang II for 24 h. Supernatants were collected 
and MCP-1 levels were evaluated by ELISA. Data are shown as 
mean±standard error of the mean (SEM) of four real-time PCR 
experiments and of three ELISA experiments. *p<0.05 vs control; 
#p<0.05 vs Ang II; †p<0.05 vs IL-1β; ¶p<0.05 vs IL-1β+Ang II.
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Figure 4. Angiotensin receptor type 1 (AT1) blockade diminished (a) nuclear factor-κB (NF-κB) activation and (c) proinflammatory 
gene upregulation. Cells were pretreated for one hour with valsartan, AT1 receptor antagonist (10–5 M) or PD123319, AT2 receptor 
antagonist (10–5 M), then cells were stimulated with 1 ng/ml interleukin-1β (IL-1β) and/or 10−7 M Ang II for 30 min (a), (b) of 18 
h (c). Part (a) shows a representative experiment of p65 NF-κB immunofluorescence staining and in (b) the immunofluorescence 
quantification as mean±standard error of the mean (SEM), of three different confocal microscopy experiments done. Part (c) shows 
percent of inhibition as mean±SEM of five real-time PCR experiments. *p<0.05 vs control; p<0.05 vs IL-1β+Ang II.
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cells to the kidney, thereby generating an inflammatory loop 
that contributes to persistent renal inflammation.
In the kidney, depending on the cell type, a different 
receptor subtype, AT1 or AT2, is involved in Ang 
II-mediated NF-κB activation.6,30,31 In MCs, vascular 
smooth muscle cells, and in AT1/AT2 transfected COS-7 
(monkey kidney fibroblast-like cell line) cells, Ang II acti-
vates the NF-κB pathway by both AT1 and AT2 recep-
tors.5,24 In tubular epithelial cells NF-κB is activated by 
AT1 receptors while in glomerular endothelial cells it is 
AT2 mediated.5,6 The existence of the AT2/NF-κB pathway 
has been further demonstrated using specific AT2 agonists, 
AT1 knockout mice24 or AT2 expressing cells.5 The Ang II 
receptor subtype involved in inflammatory processes in 
the kidney is not completely elucidated. Experimental 
studies in models of renal injury have found that both AT1 
and AT2 antagonists decreased NF-κB activation, as 
observed in the model of unilateral ureteral obstruction.30 
Moreover, in this model only combination of AT1 and AT2 
antagonists blocked monocyte infiltration; NF-κB activa-
tion; and up-regulation of NF-κB–regulated proinflamma-
tory genes, including MCP-1 and IL-6.30 Data from AT2 
knockout mice showed that the absence of AT2 signalling 
was associated with increased renal injury and mortality in 
chronic kidney disease.32 In cultured cells Ang II via the 
AT1/NF-κB pathway upregulates MCP-1, IL-6 and 
VCAM-1.26,33,34 In glomerular endothelial cells Ang II via 
AT2 upregulates gene expression of RANTES (CCL5), 
another chemokine under NF-κB control.35 In cultured 
MCs we have found that only the AT1, but not AT2, recep-
tor antagonist abolished the synergistic effect on NF-κB 
activation and proinflammatory genes caused by coincu-
bation of Ang II and IL-1β. Our data highlight the impor-
tance of the AT1/NF-κB pathway in the regulation of 
inflammatory response. Interestingly, in vascular cells 
IL-1β upregulated AT1 mRNA, increased AT1 binding after 
24 h and enhanced Ang II–stimulated hypertrophic 
responses.36 We observed that in MCs IL-1β also upregu-
lated AT1 mRNA (data not shown), and enhanced proin-
flammatory-related events. Previous studies have reported 
the presence of NF-κB recognition sites in the 5’-flanking 
region of the rat AT1 receptor.37 Moreover, the role of 
NF-κB in AT1 regulation has been demonstrated in cardiac 
fibroblasts exposed to TNFα.38 Therefore another target of 
the AT1/NF-κB pathway could be the AT1 receptor.
In conclusion, there is substantial in vitro and in vivo 
evidence, demonstrated in part by our group, that binding 
of Ang II to AT1 receptors leads to the activation of the 
canonical NF-κB pathway as well as κB-dependent genes 
in intrinsic renal cells and the kidney.2,39 Many experimen-
tal studies have demonstrated that NF-κB inhibition ame-
liorates renal injury, including in Ang II-induced tissue 
damage,3,40 however the potential use of NF-κB inhibitors 
in human kidney disease is far from actual practice. 
Experimental studies have shown that blockade of the RAS 
diminished both renal NF-κB activation and inflamma-
tion.1,2 Data presented here show that AT1 blockade inhibits 
the amplification of the inflammatory response induced by 
the simultaneous presence of Ang II and the proinflamma-
tory cytokine IL-1β, by the modulation of the NF-κB path-
way. These data suggest that in human renal inflammatory 
conditions, beneficial effects of treatment with AT1 antago-
nists, besides its well-known effects on blood pressure 
regulation, could exert additional anti-inflammatory prop-
erties by modulating Ang II-induced pathological effects, 
including cytokine-induced NF-κB activation.
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Figure 5. (a) Angiotensin II (Ang II) did not upregulate 
interleukin-1β (IL-1β) gene expression in cultured mesangial 
cells (MCs). MCs were treated with 1 ng/ml IL-1β and/or 10−7 
M Ang II for 18 h. IL-1β gene expression was measured by 
real-time PCR. Figure shows data of mean±standard error of 
the mean (SEM) of three independent experiments. (b) IL-1β 
receptor protein levels in MCs. Cells were treated with 1 ng/
ml IL-1β and/or 10−7 M Ang II for 24 h. Figure shows in top 
panel data of mean±standard error of the mean (SEM) of four 
experiments and in bottom a representative Western blot. α-
Tubulin is used as loading control.*p<0.05 vs control.
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